Lonza Unveils New TheraPEAK® Products to Enhance Gene Therapy Production

Lonza has introduced two innovative products, the TheraPEAK® AmpliCell® Cytokines and TheraPEAK® 293-GT® Medium, aimed at enhancing the manufacturing processes for cell and gene therapies. This launch expands the company’s Good Manufacturing Practice (GMP) solutions, providing scalable options for both research and clinical workflow applications.

The TheraPEAK® AmpliCell® Cytokines are engineered through a mammalian expression system to ensure high biological activity. These cytokines facilitate the expansion, activation, and differentiation of immune cells, maintaining native-like structure and function that bacterial systems cannot achieve. With a focus on batch consistency, the product is tailored for sensitive applications, ensuring reliable results across different uses.

In parallel, the TheraPEAK® 293-GT® Medium is a chemically defined, animal-origin-free solution optimized for adeno-associated virus (AAV) production in suspension HEK293 cells. This medium is designed to integrate seamlessly into existing workflows and supports commercially available transfection reagents. It promises strong AAV titers with high full-to-empty capsid ratios, making it a scalable solution for gene therapy programs.

Advancing Cell and Gene Therapy

According to Lonza, these new offerings are already being utilized in FDA-approved therapies and over 130 clinical trials globally. The company emphasizes that the TheraPEAK® range provides high-performance, GMP-compatible tools that streamline workflows from discovery through to clinical development.

Mike Goetter, the Head of Bioscience, Specialized Modalities at Lonza, stated, “The introduction of AmpliCell® Cytokines and the 293-GT® Medium to our TheraPEAK® Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts.”

The launch of these products reflects Lonza’s commitment to advancing the field of biotechnology and supporting researchers and developers in creating effective therapies. By ensuring scalability and consistency, Lonza aims to meet the growing demands of the cell and gene therapy market, which is increasingly critical in the treatment of various diseases.

With these innovations, Lonza positions itself as a key player in the biopharmaceutical industry, enabling more efficient and reliable production methods that can lead to significant advancements in patient care.